Delving into the Latest Updates on HEISCO-149 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

RT

Action

inhibitors

Mechanism

RT inhibitors(Viral reverse transcriptase inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication-

Inactive Indication

Hepatitis B, Chronic

Originator Organization

Sichuan Haisco Pharmaceutical Co., Ltd.

Active Organization-

Inactive Organization

Haisco Pharmaceutical Group Co., Ltd.

License Organization-

Drug Highest PhaseSuspendedClinical

First Approval Date-

RegulationSpecial Review Project (China)

Login to view timeline

主要目的：健康成年受试者空腹状态下交叉口服受试制剂（HEISCO-149片，海思科医药集团股份有限公司）和参比制剂（丙酚替诺福韦片，商品名：Vemlidy®/韦立得®，Gilead Sciences International Ltd），初步评价两种制剂在空腹状态下的生物等效性，为正式试验提供参考。次要目的：评价丙酚替诺福韦片在健康成年受试人群中的安全性。

[Translation]

Primary objective: To cross-administer the test preparation (HEISCO-149 tablets, HEISCO Pharmaceutical Group Co., Ltd.) and the reference preparation (tenofovir alafenamide tablets, trade name: Vemlidy®/威立德®, Gilead Sciences International Ltd) orally to healthy adult subjects in the fasting state, and preliminarily evaluate the bioequivalence of the two preparations in the fasting state to provide a reference for the formal trial. Secondary objective: To evaluate the safety of tenofovir alafenamide tablets in healthy adult subjects.

Start Date06 Jan 2020

Sponsor / Collaborator

Haisco Pharmaceutical Group Co., Ltd.

[+2]

100 Clinical Results associated with HEISCO-149

Login to view more data

100 Translational Medicine associated with HEISCO-149

Login to view more data

100 Patents (Medical) associated with HEISCO-149

Login to view more data

100 Deals associated with HEISCO-149

Login to view more data